Celera Added to Nasdaq Biotech Index; Decode, Orchid Bounced | GenomeWeb
NEW YORK (GenomeWeb News) – Nasdaq announced that it has completed its semi-annual ranking of the Nasdaq Biotechnology Index, and as a result Celera will be added to the index as of the opening of trade on Nov. 24.
 
While Celera was added, Decode Genetics and Orchid Cellmark have been dropped from the index.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.